Home Brain Tumors Impact on Cancer Patient Organisations Worldwide in 2020 – IBTA

Impact on Cancer Patient Organisations Worldwide in 2020 – IBTA

First Coalition Connection event sees publication of report showing devastating impact of COVID-19 on cancer organisations 

On 4th February 2021, the Global Cancer Coalitions Network (GCCN) held its first Coalition Connection event. Coinciding with World Cancer Day, this interactive session explored the effects that the COVID-19 pandemic has had on the global cancer community.

Formed in the wake of COVID-19, the Global Cancer Coalitions Network (GCCN) is a collaboration of nine global cancer coalitions and alliances (including the International Brain Tumour Alliance – IBTA), representing 750 patient organisations working on behalf of 14 million cancer patients around the world.

GCCN member organisations are:

  • ABC Global Alliance
  • Global Colon Cancer Association
  • Global Lung Cancer Coalition
  • International Brain Tumour Alliance
  • International Kidney Cancer Coalition
  • Lymphoma…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Lower-Dose Hypofractionated Radiotherapy Schedule Proves Effective for Patients With Locally Advanced Bladder Cancer

Using a hypofractionated schedule of 55 Gy in 20 fractions over 4 weeks to treat patients with locally advanced bladder cancer was noninferior to...

Study Identifies New Biomarker Which Could Predict Response to CD40 Immunotherapy in Pancreatic Cancer

Research published in JCI Insight identified systemic inflammation as a possible resistance mechanism to a CD40–based chemoimmunotherapy in patients with advanced pancreatic cancer.1According to...

Significant Interfacility Variation Found in Implementation of Low-Value Breast Cancer Procedures

A number of facility-level characteristics were associated with the use of low-value breast cancer procedures, and interfacility variation presented an opportunity for formal de-implementation...

KarMMa Trial Results for Ide-Cel in Refractory Myeloma Show Favorable Efficacy

Chimeric antigen receptor (CAR) T-cell therapy with idecabtagene vicleucel (ide-cel) induced responses in almost 75% of patients with multiple myeloma following relpase on multiple...

Recent Comments